Long Non-Coding RNA and Chemoresistance in Bladder Cancer – A Mini Review

Abstract

Bladder cancer is the 10th most common cancer worldwide. It is a heterogeneous disease, comprising several tumor subtypes with differences in histology, genomic aberrations, prognosis and sensitivity to anti-cancer treatments. Although the treatment of bladder cancer is based tumor classifications and gradings, patients have different clinical response. In recent years, long non-coding RNAs (lncRNAs) were associated with bladder cancer chemoresistance. Thus, lncRNAs seem to be promising targets in treatment of bladder cancer. This review highlights the recent findings concerning lncRNAs and their relevance to the chemoresistance of bladder cancer. This may provide a basis for exploiting more robust therapeutic approaches in the future.

Keywords:

• Bladder cancer
• chemoresistance
• lncRNA

Author contributions

Ana Paula Braga Lima and Glenda Nicioli da Silva wrote the manuscript.

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

Additional information

Funding

This study was supported by Universidade Federal de Ouro Preto [grant number 23109.004080/2019-88], Coordenação de Aperfeiçoamento de Pessoal de Nível Superior [Finance Code 001] and Conselho Nacional de Desenvolvimento Científico e Tecnológico [grant number CNPq-310905/2020-6, CNPq Research Productivity Scholarship].